Long-term remission of severe psoriasis following CD19-directed chimeric antigen receptor T-cell therapy for follicular lymphoma
Clinical and Experimental Dermatology · 2026
DOI: 10.1093/ced/llag301 ↗Kurz gefasst
Fallbericht in der Zeitschrift Clinical and Experimental Dermatology, 2026. Verfasst von Wayne P Gulliver und 8 weiteren Autor:innen. Beteiligte Einrichtung: Memorial University of Newfoundland, St John's, Newfoundland and Labrador, Canada. Hauptthemen laut MEDLINE: Psoriasis, Lymphoma, Follicular, Antigens, CD19, Immunotherapy, Adoptive. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 11 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Abstract (Originalsprache)
Psoriasis is a chronic, immune-mediated inflammatory disease in which durable, treatment-free remission is rarely achieved despite highly effective biologic therapies. We report a 60-year-old woman with a 49-year history of severe plaque psoriasis who developed complete and sustained disease clearance following autologous CD19-directed chimeric antigen receptor T-cell (CAR-T) therapy for follicular lymphoma. Psoriasis resolved within 4 weeks of CD19 CAR-T therapy, and the patient has remained in remission for 5 years without any psoriasis-directed treatment. This observation, together with emerging reports, suggests that deep tissue depletion of B-lymphoid lineage cells in psoriasis may induce long-term disease modification. Mechanistically, CD19 CAR-T therapy targets a broader spectrum of B-cell populations than anti-CD20 approaches, potentially disrupting pathogenic B–T-cell interactions and autoreactive immune circuits. These findings challenge the prevailing T-cell-centric paradigm of psoriasis and support exploration of B-cell-directed, immune reset strategies as a route towards durable remission or cure.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- Memorial University of Newfoundland, St John's, Newfoundland and Labrador, Canada.
- NewLab Clinical Research Inc., St John's, Newfoundland and Labrador, Canada.
- Temerty Faculty of Medicine, University of Toronto, Toronto, ON, Canada.
- 2nd Department of Dermatology, Colentina Hospital, "Carol Davila" University of Medicine and Pharmacy, Bucharest, Romania.
- Department of Medicine, University of Toronto, Toronto, ON, Canada.
- The Lynde Institute for Dermatology and Lynderm Research Inc., Markham, ON, Canada.
ORCID-Profile: Wayne P Gulliver, Jonah W Perlmutter, Susanne R Gulliver, George-Sorin Tiplica, Charles W Lynde, Robert Gniadecki, Harold Atkins, Christopher E M Griffiths, Su M Lwin
Zitieren
APA
Gulliver, W. P., Perlmutter, J. W., Gulliver, S. R., Tiplica, G. S., Lynde, C. W., Gniadecki, R., Atkins, H., Griffiths, C. E. M., & Lwin, S. M. (2026). Long-term remission of severe psoriasis following CD19-directed chimeric antigen receptor T-cell therapy for follicular lymphoma. Clinical and Experimental Dermatology. https://doi.org/10.1093/ced/llag301
Vancouver
Gulliver WP, Perlmutter JW, Gulliver SR, Tiplica GS, Lynde CW, Gniadecki R, et al. Long-term remission of severe psoriasis following CD19-directed chimeric antigen receptor T-cell therapy for follicular lymphoma. Clinical and Experimental Dermatology. 2026. doi:10.1093/ced/llag301
BibTeX
@article{Gulliver2026,
author = {Gulliver, Wayne P and Perlmutter, Jonah W and Gulliver, Susanne R and Tiplica, George-Sorin and Lynde, Charles W and Gniadecki, Robert and Atkins, Harold and Griffiths, Christopher E M and Lwin, Su M},
title = {Long-term remission of severe psoriasis following CD19-directed chimeric antigen receptor T-cell therapy for follicular lymphoma},
journal = {Clinical and Experimental Dermatology},
year = {2026},
doi = {10.1093/ced/llag301}
}
EUVIMED